Rebif and Erbitux prop Merck KGaA's Q3 sales
This article was originally published in Scrip
Executive Summary
Merck KGaA reported a 3% increase in group revenues in the third quarter, to €1.94 billion, with strong growth in sales of the multiple sclerosis drug Rebif (interferon beta-1a) and the anticancer Erbitux (cetuximab) bolstering the figure.